FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135446504> ?p ?o ?g. }

• W3135446504 endingPage "540.e1" @default.
• W3135446504 startingPage "530" @default.
• W3135446504 abstract "Rationale & Objective The associations of the glomerular markers of kidney disease, estimated glomerular filtration rate (eGFR) and albuminuria, with frailty and cognition are well established. However, the relationship of kidney tubule injury and dysfunction with frailty and cognition is unknown. Study Design Observational cross-sectional study. Setting & Participants 2,253 participants with eGFR < 60 mL/min/1.73 m2 in the Systolic Blood Pressure Intervention Trial (SPRINT). Exposure Eight urine biomarkers: interleukin 18 (IL-18), kidney injury molecule 1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), chitinase-3-like protein 1 (YKL-40), monocyte chemoattractant protein 1 (MCP-1), α1-microglobulin (A1M), β2-microglobulin (B2M), and uromodulin (Umod). Outcome Frailty was measured using a previously validated frailty index (FI), categorized as fit (FI ≤ 0.10), less fit (0.10 < FI ≤ 0.21), and frail (FI > 0.21). Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA). Analytical Approach Associations between kidney tubule biomarkers with categorical FI were evaluated using multinomial logistic regression with the fit group as the reference. Cognitive function was evaluated using linear regression. Models were adjusted for demographic, behavioral, and clinical variables including eGFR and urine albumin. Results Three of the 8 urine biomarkers of tubule injury and dysfunction were independently associated with FI. Each 2-fold higher level of urine KIM-1, a marker of tubule injury, was associated with a 1.22 (95% CI, 1.01-1.49) greater odds of being in the frail group. MCP-1, a marker of tubulointerstitial fibrosis, was associated with a 1.30 (95% CI, 1.04-1.64) greater odds of being in the frail group, and A1M, a marker of tubule reabsorptive capacity, was associated with a 1.48 (95% CI, 1.11-1.96) greater odds of being in the frail group. These associations were independent of confounders including eGFR and urine albumin, and were stronger than those of urine albumin with FI (1.15 [95% CI, 0.99-1.34]). Higher urine B2M, another marker of tubule reabsorptive capacity, was associated with worse cognitive scores at baseline (β: −0.09 [95% CI, −0.17 to −0.01]). Urine albumin was not associated with cognitive function. Limitations Cross-sectional design, and FI may not be generalizable in other populations. Conclusions Urine biomarkers of tubule injury, fibrosis, and proximal tubule reabsorptive capacity are variably associated with FI and worse cognition, independent of glomerular markers of kidney health. Future studies are needed to validate these results among other patient populations. The associations of the glomerular markers of kidney disease, estimated glomerular filtration rate (eGFR) and albuminuria, with frailty and cognition are well established. However, the relationship of kidney tubule injury and dysfunction with frailty and cognition is unknown. Observational cross-sectional study. 2,253 participants with eGFR < 60 mL/min/1.73 m2 in the Systolic Blood Pressure Intervention Trial (SPRINT). Eight urine biomarkers: interleukin 18 (IL-18), kidney injury molecule 1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), chitinase-3-like protein 1 (YKL-40), monocyte chemoattractant protein 1 (MCP-1), α1-microglobulin (A1M), β2-microglobulin (B2M), and uromodulin (Umod). Frailty was measured using a previously validated frailty index (FI), categorized as fit (FI ≤ 0.10), less fit (0.10 < FI ≤ 0.21), and frail (FI > 0.21). Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA). Associations between kidney tubule biomarkers with categorical FI were evaluated using multinomial logistic regression with the fit group as the reference. Cognitive function was evaluated using linear regression. Models were adjusted for demographic, behavioral, and clinical variables including eGFR and urine albumin. Three of the 8 urine biomarkers of tubule injury and dysfunction were independently associated with FI. Each 2-fold higher level of urine KIM-1, a marker of tubule injury, was associated with a 1.22 (95% CI, 1.01-1.49) greater odds of being in the frail group. MCP-1, a marker of tubulointerstitial fibrosis, was associated with a 1.30 (95% CI, 1.04-1.64) greater odds of being in the frail group, and A1M, a marker of tubule reabsorptive capacity, was associated with a 1.48 (95% CI, 1.11-1.96) greater odds of being in the frail group. These associations were independent of confounders including eGFR and urine albumin, and were stronger than those of urine albumin with FI (1.15 [95% CI, 0.99-1.34]). Higher urine B2M, another marker of tubule reabsorptive capacity, was associated with worse cognitive scores at baseline (β: −0.09 [95% CI, −0.17 to −0.01]). Urine albumin was not associated with cognitive function. Cross-sectional design, and FI may not be generalizable in other populations. Urine biomarkers of tubule injury, fibrosis, and proximal tubule reabsorptive capacity are variably associated with FI and worse cognition, independent of glomerular markers of kidney health. Future studies are needed to validate these results among other patient populations." @default.
• W3135446504 created "2021-03-15" @default.
• W3135446504 creator A5002523167 @default.
• W3135446504 creator A5018409007 @default.
• W3135446504 creator A5021462990 @default.
• W3135446504 creator A5024425228 @default.
• W3135446504 creator A5038227871 @default.
• W3135446504 creator A5059496781 @default.
• W3135446504 creator A5071585977 @default.
• W3135446504 creator A5081292977 @default.
• W3135446504 creator A5088693852 @default.
• W3135446504 date "2021-10-01" @default.
• W3135446504 modified "2023-10-01" @default.
• W3135446504 title "Association of Urine Biomarkers of Kidney Tubule Injury and Dysfunction With Frailty Index and Cognitive Function in Persons With CKD in SPRINT" @default.
• W3135446504 cites W1972680490 @default.
• W3135446504 cites W1985329916 @default.
• W3135446504 cites W1985920977 @default.
• W3135446504 cites W1987979328 @default.
• W3135446504 cites W2005168686 @default.
• W3135446504 cites W2015902971 @default.
• W3135446504 cites W2019611075 @default.
• W3135446504 cites W2025918208 @default.
• W3135446504 cites W2036943054 @default.
• W3135446504 cites W2061285072 @default.
• W3135446504 cites W2067970428 @default.
• W3135446504 cites W2083970331 @default.
• W3135446504 cites W2103868761 @default.
• W3135446504 cites W2109408106 @default.
• W3135446504 cites W2115931410 @default.
• W3135446504 cites W2118625269 @default.
• W3135446504 cites W2119923857 @default.
• W3135446504 cites W2128065819 @default.
• W3135446504 cites W2129700906 @default.
• W3135446504 cites W2130782777 @default.
• W3135446504 cites W2156896668 @default.
• W3135446504 cites W2166902802 @default.
• W3135446504 cites W2170588662 @default.
• W3135446504 cites W2190647908 @default.
• W3135446504 cites W2191271882 @default.
• W3135446504 cites W2195791173 @default.
• W3135446504 cites W2295988053 @default.
• W3135446504 cites W2309307446 @default.
• W3135446504 cites W2398624167 @default.
• W3135446504 cites W2402203869 @default.
• W3135446504 cites W2412338264 @default.
• W3135446504 cites W2475261460 @default.
• W3135446504 cites W2561821185 @default.
• W3135446504 cites W2561856869 @default.
• W3135446504 cites W2563736285 @default.
• W3135446504 cites W2598290521 @default.
• W3135446504 cites W2911416246 @default.
• W3135446504 cites W2912533302 @default.
• W3135446504 cites W2942934380 @default.
• W3135446504 cites W2956045949 @default.
• W3135446504 cites W2964983939 @default.
• W3135446504 cites W3006865960 @default.
• W3135446504 cites W3011206199 @default.
• W3135446504 cites W3025008845 @default.
• W3135446504 cites W3037568390 @default.
• W3135446504 cites W3150595609 @default.
• W3135446504 cites W4211203344 @default.
• W3135446504 doi "https://doi.org/10.1053/j.ajkd.2021.01.009" @default.
• W3135446504 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8390569" @default.
• W3135446504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33647393" @default.
• W3135446504 hasPublicationYear "2021" @default.
• W3135446504 type Work @default.
• W3135446504 sameAs 3135446504 @default.
• W3135446504 citedByCount "11" @default.
• W3135446504 countsByYear W31354465042021 @default.
• W3135446504 countsByYear W31354465042022 @default.
• W3135446504 countsByYear W31354465042023 @default.
• W3135446504 crossrefType "journal-article" @default.
• W3135446504 hasAuthorship W3135446504A5002523167 @default.
• W3135446504 hasAuthorship W3135446504A5018409007 @default.
• W3135446504 hasAuthorship W3135446504A5021462990 @default.
• W3135446504 hasAuthorship W3135446504A5024425228 @default.
• W3135446504 hasAuthorship W3135446504A5038227871 @default.
• W3135446504 hasAuthorship W3135446504A5059496781 @default.
• W3135446504 hasAuthorship W3135446504A5071585977 @default.
• W3135446504 hasAuthorship W3135446504A5081292977 @default.
• W3135446504 hasAuthorship W3135446504A5088693852 @default.
• W3135446504 hasBestOaLocation W31354465041 @default.
• W3135446504 hasConcept C126322002 @default.
• W3135446504 hasConcept C159641895 @default.
• W3135446504 hasConcept C2776174234 @default.
• W3135446504 hasConcept C2778653478 @default.
• W3135446504 hasConcept C2780026642 @default.
• W3135446504 hasConcept C2780472472 @default.
• W3135446504 hasConcept C71924100 @default.
• W3135446504 hasConcept C74460091 @default.
• W3135446504 hasConceptScore W3135446504C126322002 @default.
• W3135446504 hasConceptScore W3135446504C159641895 @default.
• W3135446504 hasConceptScore W3135446504C2776174234 @default.
• W3135446504 hasConceptScore W3135446504C2778653478 @default.
• W3135446504 hasConceptScore W3135446504C2780026642 @default.
• W3135446504 hasConceptScore W3135446504C2780472472 @default.
• W3135446504 hasConceptScore W3135446504C71924100 @default.
• W3135446504 hasConceptScore W3135446504C74460091 @default.

• next